Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 11, 2025Revista de MedicinaOpen Access

Anticoagulação na Fibrilação Atrial: uma análise integrativa retrospectiva dos riscos hemorrágicos de Apixabana e Varfarina

View Full Paper
Ask AI
Bookmark
Share

Authors

CTCamila Arrelaro ToscanoMSMarcelo Luiz Peixoto SobralPRPriscila Barão Rocha

Discussion

Loading...

Member takes

Overview

Retrospective review reveals lower bleeding rates for apixaban compared to warfarin in AF patients, highlighting safety benefits.

Key Points

  • Apixaban is associated with significantly lower major bleeding events than warfarin in atrial fibrillation patients.
  • Major bleeding rates were 3.09% for warfarin versus 2.13% for apixaban over a 20-month follow-up period.
  • This retrospective integrative review analyzed studies from 2017 to 2022 to assess drug safety in treating atrial fibrillation.
  • The findings support the use of apixaban as a first-line anticoagulant due to its favorable safety profile.

Cite This Study

Toscano et al. (2025) studied this question.

synapsesocial.com/papers/68af2eeacf1dd9ea359e69f7https://doi.org/10.11606/issn.1679-9836.v104i4e-207053
View Full Paper
Ask AI
Bookmark
Share